Chenli Xu

机构：Shanxi Medical University, Nantong University, Huahai Pharmaceutical (China), Ministry of Education, Second Hospital of Shanxi Medical University, Zhejiang Medicine (China)

发表论文 12 篇 · 总被引 90 次 · h-index 3

代表论文

• Tooth loss and cancer risk: a dose-response meta analysis of prospective cohort studies (2017 · Oncotarget · 被引 48)
• Nonsteroidal anti-inflammatory drugs using and risk of head and neck cancer: a dose-response meta analysis of prospective cohort studies (2017 · Oncotarget · 被引 31)
• Effects of Sensory‐Based Interventions on Delirium Prevention in Critically Ill Patients: A Systematic Review and Meta‐Analysis (2025 · International Journal of Nursing Practice · 被引 5)
• Identification and Verification of a Novel Disulfidptosis-Related lncRNAs Prognostic Signature to Predict the Prognosis and Immune Activity of Head and Neck Squamous Carcinoma (2024 · Iranian Journal of Public Health · 被引 3)
• FOLR1‐stabilized β‐catenin promotes laryngeal carcinoma progression through EGFR/AKT/GSK‐3β pathway (2023 · Molecular Carcinogenesis · 被引 3)
• Design, synthesis and biological evaluation of novel substituted pyrazole-hydrazine hybrids as potent and safe anti-leukemia agents (2026 · Journal of Molecular Structure)